A look at what to expect at AAGL's 45th congress.
The 45th AAGL Global Conference starts today in Orlando, Florida with the theme “Advancing Minimally Invasive Gynecology through Mentorship and Emerging Technology.” The Congress promises a wealth of learning opportunities with postgraduate courses, surgical tutorials, and panel discussions.
As always the Congress will touch on timely topics such as tissue extraction, the controversies surrounding Essure, diagnosis and treatment of isthmoceles, cosmetogynecology, and radio-frequency ablation for fibroids. Physicians looking to brush up with continuing medical education can choose from 5 general sessions, 8 panel sessions, 8 plenary sessions, 7 surgical tutorials, and 25 postgraduate courses. Educational content will touch on related subspecialties like oncology, urogynecology, and infertility. More than 870 abstracts will be presented over 5 days.
Popular Congress features like Stump the Professor and telesurgery sessions will be returning. This year’s keynote address by Scott Parazynski, MD, will cover his experiences as an entrepreneur-innovator who worked with multidisciplinary teams and discuss the need to promote innovation and mentorship to benefit healthcare.
Plus, the Contemporary OB/GYN team will be there to give you the data you need. Be sure to visit us at Booth #1315.
Hormone therapy safety: Study finds potential benefits for senior women
April 24th 2024A recent large-scale study challenged age-related concerns, suggesting hormone therapy may offer safety and even benefits for menopausal women aged over 65 years, aligning with The Menopause Society's 2022 Position Statement.
Read More
Hyperoxygenation use not linked to neonatal outcomes
April 23rd 2024Recent research evaluated the impact of maternal hyperoxygenation on neonatal Apgar scores, revealing no significant enhancement in outcomes among women with pathologic fetal heart rate tracing and suggesting limited efficacy of hyperoxygenation therapy in this context.
Read More
Study finds antihypertensive treatment reduces uterine fibroids risk
April 23rd 2024A recent study revealed that patients with untreated or new-onset hypertension face elevated chances of uterine fibroid diagnosis, underscoring the potential of antihypertensive therapy in mitigating this risk among midlife individuals.
Read More